26rhk079 10.3205/26rhk079 urn:nbn:de:0183-26rhk0793 Meeting Abstract Thürmel Thürmel Klaus K

Augustinum Klinik München, Augustinum Klinik München, Nephrologie, Rheumatologie, München, Deutschland

author Oestreich Oestreich Laura L

LMU-Klinikum, LMU-Klinikum, Med III, AG Versorgungsforschung, München, Deutschland

author Becht Becht Selina S

LMU, Med III, AG Versorgungsforschung, München, Deutschland

author Berger Berger Karin K

LMU, Med III, AG Versorgungsforschung, München, Deutschland

author Schönermarck Schönermarck Ulf U

LMU-Klinikum, LMU-Klinikum, Medizinische Klinik und Poliklinik IV, München, Deutschland

author German Medical Science GMS Publishing House

Düsseldorf

610 20260909 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0656 079 Deutsche Gesellschaft für Rheumatologie Deutsche Gesellschaft für Orthopädische Rheumatologie Gesellschaft für Kinder- und Jugendrheumatologie 54. Kongress der Deutschen Gesellschaft für Rheumatologie und Klinische Immunologie (DGRh), 36. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR), 40. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh) Deutscher Rheumatologiekongress 2026 Epidemiologie & Versorgungsforschung Leipzig 20260909 20260912 EV.33 TextIntroduction: Management of ANCA (Anti-Neutrophil Cytoplasmic Antibodies)-associated vasculitis (AAV) requires a multidisciplinary, cross-sectoral, patient-centered approach, which is challenging in a fragmented health care system. Basic information for the development and implementation of optimized care models includes patient care pathways, time from first symptom onset to diagnosis and treatment, quality of care coordination, and needs from patients’ perspective. This study, within the AVANTI initiative, aims to systematically assess the aforementioned information needs, for which evidence to date remains very limited.Methods: This mixed-methods study investigates patients with AAV, including granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA), by integrating qualitative and quantitative phases using a triangulation approach. The qualitative phase consisted of exploratory semi-structured interviews, which informed the development of a structured questionnaire for a nationwide online survey. Participants are being recruited through office-based practices, inpatient and outpatient hospital settings, patient advocacy groups, and social media. Data will be analyzed descriptively, with stratification by age, disease subtype, and geographic region.Results: Qualitative phase: Ten patients (6 female; mean age 59, range 25–87) reported heterogeneous care pathways. Average time from symptom onset to first physician contact was 48 days (median 21), followed by 50 days to diagnosis (median 30). Patients consulted up to four doctors before diagnosis. Half of the participants used supportive services, and seven reported unmet needs for information on diagnosis and treatment side effects. Quantitative phase: Recruitment began in March via patient advocacy groups and social media, with 193 patients completing the survey (mean age 58, SD 14, range 23–92). Recruitment at 20 additional centers subsequently started and will continue until end of April 2026.Conclusion: The exploratory interviews revealed signals of heterogeneity in AAV care pathways in the German healthcare setting. They also highlight challenges in time to diagnosis, care coordination, and patient information. The subsequent quantitative survey serves to quantify the identified aspects and signals across a larger sample. Final data analysis of the quantitative part is not yet complete at the time of abstract submission and will be available by the time of the conferenceDisclosures: LO, SB: keineKB: Forschungsunterstützung: CSL ViforUS: Advisory Board/Studienteilnahme: CSL Vifor, Alexion/AstraZeneca, Genzyme-Sanofi, Hansa Biopharma, Sobi, Novartis; Vortragshonorar: CSL Vifor, NovartisKT: Advisory Board/Vortragshonorare/Kongressunterstützung: CSL Vifor/GSK/Boehringer/AstraZeneca/Alpha-Sigma 0 0 0 0